Vensana Capital

Evident Vascular specializes in advanced intravascular ultrasound (IVUS) technology, enhanced by artificial intelligence. Their platform automatically identifies and segments key vascular structures in real-time, aiding clinicians in decision-making and improving patient care during peripheral vascular image-guided therapies.

Alleviant Medical, Inc. is a medical device company headquartered in Austin, Texas, that specializes in developing innovative therapies for congestive heart failure. Founded in 2017, the company has created a proprietary transcatheter device that addresses the symptoms of heart failure by relieving pressure buildup in the left atrium of the heart. This minimally-invasive technology aims to improve the quality of life for patients and significantly reduce hospital admissions related to heart failure exacerbations, ultimately benefiting millions of Americans affected by this condition. Alleviant Medical is committed to transforming the treatment landscape for congestive heart failure through its advanced medical devices.

Okami Medical, Inc. is a medical device manufacturer based in Aliso Viejo, California, specializing in the occlusion of peripheral vessels to treat cardiovascular disease. The company's flagship product, the LOw-profile Braided Occluder (LOBO), is designed to provide interventional physicians with a single, versatile device for occluding various arterial targets without the need for multiple embolic devices. The LOBO system features a patented design and proprietary HDBRAID technology, which creates a highly occlusive pore structure that effectively reduces blood flow and accelerates vessel closure. Founded in 2011, Okami Medical aims to meet the evolving needs of patients and healthcare providers by offering innovative solutions that ensure rapid and reliable vessel occlusion, regardless of anatomical challenges.

iVEAcare is a company focused on developing innovative neuromodulation therapies to address unmet clinical needs in chronic disease management. The firm specializes in next-generation technology that delivers targeted electrical stimulation to specific areas of the brain or spinal cord. By creating advanced devices and software, iVEAcare aims to enable medical professionals to devise therapies that are both more effective and less invasive than traditional treatment methods. This approach not only enhances treatment efficacy but also broadens access to therapies for a wider range of patients suffering from chronic conditions.

Elucent Medical LLC is a healthcare company focused on enhancing breast cancer treatment. Established in 2014 and headquartered in Brookfield, Wisconsin, Elucent Medical creates and commercializes a wireless marker tag and detection system that improves the localization of breast abnormalities during surgical excision. Their advanced surgical navigation technology relies on real-time data processing to accurately identify surgical markers, which helps in determining tumor margins and ultimately contributes to better patient outcomes. By streamlining the surgical process and eliminating the need for traditional metal clips, Elucent Medical aims to make breast cancer procedures more accessible and affordable while enabling surgeons to effectively preserve breast tissue during cancer removal. The company's innovations serve both healthcare providers and patients, enhancing the overall efficacy of breast cancer surgeries.

Evident Vascular specializes in advanced intravascular ultrasound (IVUS) technology, enhanced by artificial intelligence. Their platform automatically identifies and segments key vascular structures in real-time, aiding clinicians in decision-making and improving patient care during peripheral vascular image-guided therapies.

SpyGlass Pharma specializes in developing innovative treatments for chronic ophthalmic diseases through advanced technology. The company creates ophthalmic devices and a drug delivery platform aimed at enhancing vision and eye care for patients. Its products address unmet needs in areas such as cataracts, lens replacement, and surgical procedures. The drug delivery platform is designed to be implanted alongside intraocular lenses during standard cataract surgeries, allowing for the provision of multi-year therapy to treat chronic eye conditions. This approach not only facilitates effective treatment but also aims to make quality eye care more accessible and affordable for patients.

Artelon is a company focused on advancing orthopedic soft tissue reconstruction through innovative tissue-regrowth technology. It specializes in the development of synthetic materials specifically designed for tendon and ligament reconstruction, aiming to enhance stability and motion in affected joints. By creating bio-textiles that provide kinematic reinforcement, Artelon enables surgeons to effectively restore joint strength and functionality. The company is dedicated to improving patient outcomes in joint instability cases through its novel reconstructive products and procedures, as well as offering consulting support to aid in patient recovery.

Relievant Medsystems, Inc. is a medical device company focused on developing innovative solutions for chronic axial low back pain. Founded in 2004 and headquartered in Minneapolis, Minnesota, with a development office in Sunnyvale, California, the company has created the Intracept System. This minimally invasive procedure specifically targets the basivertebral nerve, providing relief by blocking pain signal transmission. The Intracept System offers patients a low-risk therapy option aimed at alleviating chronic vertebrogenic low back pain.

Alleviant Medical, Inc. is a medical device company headquartered in Austin, Texas, that specializes in developing innovative therapies for congestive heart failure. Founded in 2017, the company has created a proprietary transcatheter device that addresses the symptoms of heart failure by relieving pressure buildup in the left atrium of the heart. This minimally-invasive technology aims to improve the quality of life for patients and significantly reduce hospital admissions related to heart failure exacerbations, ultimately benefiting millions of Americans affected by this condition. Alleviant Medical is committed to transforming the treatment landscape for congestive heart failure through its advanced medical devices.

Volta Medical is a technology company based in Marseille, France, founded in 2016, specializing in the development of artificial intelligence software for interventional cardiology. Its primary focus is on providing innovative solutions to assist cardiologists in the treatment of atrial fibrillation, the most common cardiac arrhythmia. The company’s flagship product, AIFib, integrates AI algorithms that analyze electrograms and guides mapping catheters during interventional procedures. This sophisticated software enhances the ability of interventional cardiologists to make informed decisions and carry out patient-specific strategies for cardiac ablation, thereby improving the overall efficacy of heart surgeries. Through its commitment to advancing healthcare technology, Volta Medical aims to transform cardiac care by utilizing cutting-edge AI approaches in therapeutic applications.

Nyra Medical is focused on creating innovative transcatheter heart valve repair technology specifically designed to treat mitral regurgitation. The company develops a structural heart device that modifies the native mitral valve using a proprietary implant, which helps to maintain the physiological geometry of the valve. This approach allows for a reproducible correction of valve regurgitation, offering a potential advancement in the treatment options available for patients suffering from this condition.

Cleerly is a healthcare company focused on transforming the management of coronary artery disease through innovative digital care pathways aimed at preventing heart attacks. By combining advanced clinical science with state-of-the-art artificial intelligence, Cleerly develops a platform that delivers actionable clinical insights for all stakeholders involved in heart care. This platform employs a non-invasive approach to analyze and characterize plaque buildup in coronary arteries, allowing healthcare providers to better identify at-risk patients and facilitate early treatment. Cleerly's data-driven solutions not only enhance the evaluation of cardiovascular disease but also aim to improve patient heart health while delivering value to the healthcare system.

Moxe Health specializes in facilitating the exchange of clinical data between health plans and provider systems. Its platform, Substrate, enables real-time, bi-directional data transfer, including clinical, analytic, and administrative information. Moxe's solutions cover risk adjustment, quality metrics (like HEDIS and Star ratings), claims management, and care gap management, ensuring health plans and providers have the necessary data for value-based care. The company's neutrality allows seamless integration with existing systems, maximizing investments in population health and analytics.

Apella is an AI startup focused on enhancing surgical practices through advanced healthcare technology. Founded in 2019 and based in San Francisco, California, the company utilizes artificial intelligence and computer vision to collect and analyze data from operating rooms. By digitizing the surgical environment, Apella aims to improve operational efficiency, surgical quality, and training, while also facilitating real-time decision-making for surgeons and medical staff. Its innovative approach seeks to generate new insights that contribute to better outcomes in surgical procedures.

Cleerly is a healthcare company focused on transforming the management of coronary artery disease through innovative digital care pathways aimed at preventing heart attacks. By combining advanced clinical science with state-of-the-art artificial intelligence, Cleerly develops a platform that delivers actionable clinical insights for all stakeholders involved in heart care. This platform employs a non-invasive approach to analyze and characterize plaque buildup in coronary arteries, allowing healthcare providers to better identify at-risk patients and facilitate early treatment. Cleerly's data-driven solutions not only enhance the evaluation of cardiovascular disease but also aim to improve patient heart health while delivering value to the healthcare system.

GPB Scientific, LLC is a biotechnology company specializing in the development of a liquid biopsy platform designed to isolate rare circulating tumor cells from a patient's blood while preserving their viability. The company offers a desktop fluidic system that processes whole blood through a disposable microchip, effectively separating red blood cells and normal white blood cells to yield a population of rare tumor cells. Founded in 2002 and based in Richmond, Virginia, GPB Scientific markets its innovative technology to life sciences companies and research institutions, boasting a robust portfolio of patents and expertise in microchip technology for size-based enrichment and affinity-based cell capture.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

Spyglass Ophthalmics, Inc. is a company based in Mission Viejo, California, specializing in the development of ophthalmic therapeutic devices. Founded in 2019, Spyglass focuses on creating innovative solutions to enhance vision and eye care for patients. The company's products target unmet needs in areas such as cataract treatment, lens replacement, and other chronic ophthalmic diseases. By providing these devices, Spyglass aims to ensure that patients receive quality eye treatment at an affordable cost.

Relievant Medsystems, Inc. is a medical device company focused on developing innovative solutions for chronic axial low back pain. Founded in 2004 and headquartered in Minneapolis, Minnesota, with a development office in Sunnyvale, California, the company has created the Intracept System. This minimally invasive procedure specifically targets the basivertebral nerve, providing relief by blocking pain signal transmission. The Intracept System offers patients a low-risk therapy option aimed at alleviating chronic vertebrogenic low back pain.

CVRx, Inc. is a medical device company headquartered in Minneapolis, Minnesota, that specializes in the development of implantable technologies for the treatment of high blood pressure and heart failure. Founded in 2000, the company has created Barostim NEO, a neuro-modulation therapy that activates the body's natural mechanisms to regulate blood pressure and address heart failure progression. This therapy utilizes an implantable system that is tailored to the individual needs of patients. CVRx also offers the Rheos platform, which includes an implantable pulse generator and carotid sinus leads designed to deliver therapeutic energy to the carotid arteries. With a focus on minimally invasive solutions, CVRx primarily serves patients and healthcare professionals in the United States and internationally, including markets in the United Kingdom, the Netherlands, Italy, and Germany.

GPB Scientific, LLC is a biotechnology company specializing in the development of a liquid biopsy platform designed to isolate rare circulating tumor cells from a patient's blood while preserving their viability. The company offers a desktop fluidic system that processes whole blood through a disposable microchip, effectively separating red blood cells and normal white blood cells to yield a population of rare tumor cells. Founded in 2002 and based in Richmond, Virginia, GPB Scientific markets its innovative technology to life sciences companies and research institutions, boasting a robust portfolio of patents and expertise in microchip technology for size-based enrichment and affinity-based cell capture.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, specializing in the development of minimally invasive products for peripheral vascular procedures. Founded in 2011, the company is known for its Tack Endovascular System, which aims to enhance the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular focuses on creating safe and effective solutions that improve clinical outcomes and quality of life for patients with vascular diseases, while also providing physicians with innovative treatment options.

Vesper Medical, Inc. is a medical device company based in Wayne, Pennsylvania, founded in 2016. The company specializes in the development of minimally invasive peripheral vascular products aimed at treating patients with deep venous disease. Its primary offering is the Vesper DUO Venous Stent System, designed specifically for venous stenting. This system features a unique combination of strength and flexibility to address the complex anatomical challenges encountered in the iliac and femoral veins. Vesper Medical is dedicated to creating safe, effective, and user-friendly products that enhance patient care and support healthcare providers in improving patient outcomes in venous treatment.